1-4 of 4
Jutta Deininger
Close
Sort by
Journal Articles

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Jeffrey W. Tyner, Thomas G. Bumm, Jutta Deininger, Lisa Wood, Karl J. Aichberger, Marc M. Loriaux, Brian J. Druker, Christopher J. Burns, Emmanuelle Fantino, Michael W. Deininger
Journal: Blood
Blood (2010) 115 (25): 5232–5240.
https://doi.org/10.1182/blood-2009-05-223727
Published: 2010
Includes: Supplemental data
Journal Articles

Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD

Thomas G.P. Bumm, Jeffrey W Tyner, PhD, Jutta Deininger, Marc Loriaux, Jonathan VanDyke, Brian J. Druker, Christopher J Burns, Emmanuelle Fantino3, Michael W.N. Deininger, MD
Journal: Blood
Blood (2008) 112 (11): 856.
https://doi.org/10.1182/blood.V112.11.856.856
Published: 2008
Journal Articles

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

Anupriya Agarwal, Thomas G. P. Bumm, Amie S. Corbin, Thomas O'Hare, Marc Loriaux, Jonathan VanDyke, Stephanie G. Willis, Jutta Deininger, Keiichi I. Nakayama, Brian J. Druker, Michael W. Deininger
Journal: Blood
Blood (2008) 112 (5): 1960–1970.
https://doi.org/10.1182/blood-2007-09-113860
Published: 2008
Includes: Supplemental data
Journal Articles

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

Anupriya Agarwal, PhD, Thomas G.P. Bumm, MD, Amie Corbin, Thomas O’Hare, PhD, Marc Loriaux, MD, PhD, Stephanie G. Willis, Jutta Deininger, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 742.
https://doi.org/10.1182/blood.V108.11.742.742
Published: 2006